Colospan

growth-positive

The Israeli biotech industry is experiencing tremendous growth. There are over a thousand biotech companies in Israel employing over forty thousand workers, and some are considered leaders in the world. The biotech companies face additional challenges related to strict regulations and long development processes. ColoSpan, an Israeli biotech company, has developed a device called CG-100 that prevents leaks in the digestive system. The device has been approved for marketing by the Ministry of Health and the European Union. ColoSpan partnered with Balcam Menas to produce the first set of product templates and ensure the highest quality and precision in the product design.

growth-positive

Colospan, a company developing novel solutions for colorectal surgery, has been awarded €8.2 million ($9.3 million) from the European Innovation Council (EIC) as part of the EIC Accelerator program. The funding includes both a grant and equity financing. This funding is expected to have a growth-positive impact on the company. Colospan is one of 99 innovative start-ups and SMEs selected to receive funding from the European Commission to bring promising technologies to the market. The companys CG-100 device, an investigational device for colorectal cancer patients, is being developed and has received approval for use in the European Union, Israel, and under IDE in the USA.

growth-positive

Colospan, a medical device company specializing in colorectal surgery, has announced the appointment of Gregory D. Casciaro to its board of directors. Casciaro brings four decades of experience in the medtech industry and a track record of leading successful companies. Colospans CEO and Founder, Boaz Assaf, expressed excitement about Casciaros appointment and believes he will play a crucial role in shaping the companys future. Casciaro himself praised Colospans innovative product and expressed his enthusiasm for joining the board to improve patient lives and impact healthcare economics. Colospan is focused on addressing the challenges of anastomotic leaks in colorectal surgery and is currently conducting a multi-center randomized trial. The companys CG-100 product is not yet approved for sale in the United States. For more information, visit Colospans website.

growth-positive

Colospan Ltd. announced that Henry Ford Hospital in Detroit is the first in the U.S. to use the CG-100 bypass device in an investigational procedure for rectal cancer patients. The device aims to reduce the need for a diverting stoma and its related complications. Henry Ford Hospital is one of 12 sites nationwide participating in the clinical trial. Colorectal surgery often involves creating a stoma to divert waste from the bowel, but living with a stoma can be uncomfortable. The CG-100 device offers the potential for a more comfortable recovery and improved quality of life for patients. Colospan Ltd. is a medical device company focused on developing solutions for colorectal surgery.

growth-positive

Colospan, a medical device company based in Kfar Saba, Israel, has developed a novel temporary intraluminal bypass device called CG-100. The device is designed to reduce the rate of diverting stoma and related complications in patients undergoing gastrointestinal resection procedures. It diverts fecal material from contacting the anastomotic site during the initial healing period. The CG-100 has received approval from the European Community and an investigational device exemption from the U.S. Food and Drug Administration. Colospan plans to conduct a prospective, randomized pivotal study to bring the device closer to the market and improve patient outcomes. The device offers a short-term alternative to diverting stomas, which can cause significant complications and require a second procedure for closure.